Availability rate of new oncology medicines in Europe 2023, by country

This statistic displays the share of oncology medicines approved by the European Medicines Agency (EMA) between 2018 and 2021 which were available to patients in selected European countries as of January 5, 2023. According to the data, 98 percent of approved oncology medicines were available to patients in Germany, followed by 89 percent in Switzerland.

Percentage of oncology medicines approved by the EMA available to patients in Europe as of 2023, by country

Characteristic	Share of medicines available
Germany	98%
Switzerland	89%
Austria	83%
Italy	83%
Denmark	80%
Czech Republic	76%
England	76%
France	72%
Greece	70%
Scotland	67%
Sweden	65%
Finland	63%
Luxemburg	63%
Netherlands	63%
Belgium	57%
Spain**	57%
Norway	52%
Portugal	52%
Slovenia	50%
Bulgaria	48%
Cyprus*	48%
Poland	46%
Iceland	41%
Hungary	39%
Ireland	39%
Croatia*	35%
Romania	30%
Estonia	17%
Latvia	17%
Serbia	11%
Slovakia	11%
Lithuania	9%
North Macedonia*	9%
Turkey	9%
Albania*	7%
Bosnia and Herzegovina*	7%
Malta	2%

Loading statistic...

Download

Source

Show detailed source information?

Already a member?

Sources

Use Ask Statista Research Service

Release date

April 2023

More information

Region

Europe

Survey time period

as of January 5, 2023

Supplementary notes

46 oncology medicines were approved by the European Medicines Agency between 2018 and 2021.
In most countries availability equates to granting of access to the reimbursement list, except in DK, FI, LU. NO, SE some hospital products are not covered by the general reimbursement scheme.
* Country did not complete a full dataset and therefore availability may be unrepresentative.
** In Spain, the WAIT analysis does not identify those medicinal products being accessible earlier in conformity with Spain's Royal Decree 1015/2009 relating to Medicines in Special Situations.

Citation formats